Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Rev Argent Microbiol ; 45(1): 21-6, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23560784

RESUMEN

The relation of ethambutol resistance to embB mutations remains unclear, and there are no reports on ethambutol resistance from the caribbean. We examined the sequence of embB in 57 distinct Multi-Drug Resistant (MDR) and non-MDR strains of Mycobacterium tuberculosis, mostly from Cuba and the Dominican Republic. embB306 codon mutations were found exclusively in MDR-TB, but in both ethambutol sensitive and resistant strains. Valine substitutions predominated in ethambutol resistant strains, while isoleucine replacements were more common in sensitive strains. Three ethambutol resistant MDR strains without embB306 substitutions had replacements in embB406 or embB497, but these were also found in ethambutol sensitive MDR strains. The results confirm previous findings that amino acid substitutions in EmbB306, EmbB406 and EmbB497 are found only in MDR-TB strains but in both phenotypically resistant and sensitive strains. One ethambutol resistant non-MDR strain did not have any embB mutation suggesting that other undefined mutations can also confer ethambutol resistance.


Asunto(s)
Antituberculosos/farmacología , Farmacorresistencia Microbiana/genética , Etambutol/farmacología , Mycobacterium tuberculosis/genética , Pentosiltransferasa/genética , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Sustitución de Aminoácidos , Codón/genética , Cuba/epidemiología , Análisis Mutacional de ADN , ADN Bacteriano/genética , República Dominicana/epidemiología , Relación Dosis-Respuesta a Droga , Farmacorresistencia Bacteriana Múltiple/genética , Humanos , Pruebas de Sensibilidad Microbiana , Mutación , Mycobacterium tuberculosis/efectos de los fármacos , Pentosiltransferasa/fisiología , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología
2.
Rev Panam Salud Publica ; 30(6): 615-8, 2011 Dec.
Artículo en Español | MEDLINE | ID: mdl-22358412

RESUMEN

OBJECTIVE: Determine the prevalence of resistance to antitubercular drugs in Cuba in the 2000-2009 decade. METHODS: A prospective longitudinal study was conducted. The sample group consisted of 2,285 Mycobacterium tuberculosis isolates obtained from throughout the country in the period from 1 January 2000 to 31 December 2009. The proportion method was used in Löwenstein-Jensen media with the first-line drugs: isoniazid, streptomycin, ethambutol, and rifampicin. RESULTS: In the new cases and patients with a history of previous treatment, resistance was 8.5% and 37.0%, respectively. In these case categories, multidrug resistance was 0.4% and 8.8%, respectively. CONCLUSIONS: This study shows low prevalence of multidrug-resistant strains in Cuba. The results reflect the progress made by the national control program, which is currently working on the elimination of tuberculosis as a public health problem in the country.


Asunto(s)
Antituberculosos/farmacología , Farmacorresistencia Microbiana , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis/microbiología , Antituberculosos/uso terapéutico , Cuba/epidemiología , Farmacorresistencia Bacteriana Múltiple , Estudios de Seguimiento , Humanos , Control de Infecciones/organización & administración , Mycobacterium tuberculosis/aislamiento & purificación , Vigilancia de la Población , Prevalencia , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Tuberculosis/prevención & control , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Tuberculosis Resistente a Múltiples Medicamentos/prevención & control
3.
J Clin Microbiol ; 48(8): 2729-33, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20554826

RESUMEN

The direct detection of pyrazinamide resistance in Mycobacterium tuberculosis is sufficiently difficult that many laboratories do not attempt it. Most pyrazinamide resistance is caused by mutations that inactivate the pyrazinamidase enzyme needed to convert the prodrug pyrazinamide to its active form. We evaluated two newer and simpler methods to assess pyrazinamidase activity, the nitrate reductase and malachite green microtube assays, using nicotinamide in place of pyrazinamide. A total of 102 strains were tested by these methods and the results compared with those obtained by the classic Wayne assay. Mutations in the pncA gene were identified by sequencing the pncA genes from all isolates in which pyrazinamide resistance was detected by any of the three methods. Both the nitrate reductase and malachite green microtube assays showed sensitivities of 93.75% and specificities of 97.67%. Mutations in the pncA gene were found in 14 of 16 strains that were pyrazinamide resistant and in 1 of 4 strains that were sensitive by the Wayne assay. Both of these simple methods, used with nicotinamide, are promising and inexpensive alternatives for the rapid detection of pyrazinamide resistance in limited-resource countries.


Asunto(s)
Antituberculosos/farmacología , Colorimetría/métodos , Farmacorresistencia Bacteriana , Mycobacterium tuberculosis/efectos de los fármacos , Niacinamida/metabolismo , Pirazinamida/farmacología , Amidohidrolasas/genética , Humanos , Pruebas de Sensibilidad Microbiana/métodos , Nitratos/metabolismo , Compuestos Organometálicos/metabolismo , Sensibilidad y Especificidad , Análisis de Secuencia de ADN
4.
MEDICC Rev ; 19(1): 10-15, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-28225540

RESUMEN

INTRODUCTION Systematic surveillance of antituberculosis drug resistance allows identification of multidrug-resistant and extensively drug-resistant isolates of Mycobacterium tuberculosis. Surveillance studies of antituberculosis drug resistance systematically conducted in Cuba for over 15 years have revealed low circulation of multidrug-resistant tuberculosis, under 1% in new cases. OBJECTIVE Characterize antituberculosis drug resistance in isolates of M. tuberculosis recovered from patients with pulmonary tuberculosis in Cuba in 2012-2014. METHODS The nitrate reductase assay was used to test 997 isolates of M. tuberculosis for sensitivity to isoniazid and rifampicin. Isolates identified as multidrug resistant were tested for sensitivity to isoniazid, rifampicin, streptomycin, ethambutol, ofloxacin, amikacin, kanamycin and capreomycin by the proportion method, as well as genetic resistance mutations in rpoB, katG, inhA, gyrA, rrs and embB genes, using GenoType MTBDRplus and MTBDRsl commercial kits. RESULTS Some 95.6% of isolates from new cases and 89.6% of isolates from previously treated patients were sensitive to isoniazid and rifampicin. Multidrug resistance was found in 0.8% of new and 5.2% of previously treated patients, a statistically significant difference. One extensively drug-resistant isolate was detected among previously treated cases. All isolates examined with the molecular method had mutations in the rpoB gene, which is associated with resistance to rifampicin; only seven showed mutations in the katG gene and one in the inhA gene associated with isoniazid resistance. In one isolate, we found mutations in both gyrA and rrs genes, which are associated with resistance to fluoroquinolones and second-line injectable drugs and therefore, extensive resistance. CONCLUSIONS Results corroborate the low frequency of multidrug-resistant and extensively resistant M. tuberculosis strains in Cuba and highlight the need for continuous improvement of surveillance of antituberculosis drug resistance in Cuba. KEYWORDS Mycobacterium tuberculosis, multidrug resistance, extensively drug-resistant tuberculosis, Cuba.


Asunto(s)
Antituberculosos/uso terapéutico , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Estudios Transversales , Farmacorresistencia Microbiana/genética , Tuberculosis Extensivamente Resistente a Drogas/tratamiento farmacológico , Tuberculosis Extensivamente Resistente a Drogas/epidemiología , Tuberculosis Extensivamente Resistente a Drogas/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Mycobacterium tuberculosis/genética , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/microbiología
5.
Tuberculosis (Edinb) ; 86(3-4): 319-23, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16569512

RESUMEN

SETTING: The spread of multidrug-resistant tuberculosis (MDR TB) in the world remains a major public health problem. Surveillance of anti-TB drug resistance is therefore an essential tool for monitoring the effectiveness of TB control program and, through policy development, for improving national and global TB control. OBJECTIVE: To determine the prevalence of anti-TB drug resistance in Cuba during the execution of the three global projects. DESIGN: Drug-resistance was determined using the proportion method in 1528 Mycobacterium tuberculosis strains to first line anti-TB drugs. RESULTS: Resistance in new cases was 8.3%, 4.6% and 5.0%; MDR was 0.7%, 0% and 0.3% in the first (1997), second (2000) and third (2004) global projects, respectively. In new cases, none showed resistance to the four drugs. There were among previously treated cases statistically significant decreases in the prevalence of resistance to at least one drug when comparing the results obtained in the three global projects. CONCLUSIONS: The contributed data through Cuba demonstrated that our country is relatively free of MDR strains, reflecting the good National Control Program and the possibility of TB elimination in Cuba.


Asunto(s)
Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Antituberculosos/farmacología , Cuba/epidemiología , Farmacorresistencia Bacteriana , Farmacorresistencia Bacteriana Múltiple , Humanos , Pruebas de Sensibilidad Microbiana/métodos , Mycobacterium tuberculosis/efectos de los fármacos , Vigilancia de la Población , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/microbiología
6.
J Med Microbiol ; 55(Pt 7): 861-863, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16772412

RESUMEN

The nitrate reductase assay (NRA) was used as an alternative method for detection of resistance to the first-line antituberculous drugs isoniazid, rifampicin, ethambutol and streptomycin. A total of 320 strains of Mycobacterium tuberculosis were studied and the results compared with the proportion method (PM) on Löwenstein-Jensen medium. The mean time to obtain results was 10 days and the overall agreement between the NRA and PM was 98.8 %. The NRA was easy to perform and represents a useful tool for rapid and accurate determination of drug-resistant M. tuberculosis strains in low-resource countries.


Asunto(s)
Antituberculosos/farmacología , Mycobacterium tuberculosis/efectos de los fármacos , Nitrato-Reductasa/metabolismo , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Colorimetría/métodos , Humanos , Mycobacterium tuberculosis/aislamiento & purificación , Nitritos/análisis
7.
Ann Clin Microbiol Antimicrob ; 5: 11, 2006 Apr 21.
Artículo en Inglés | MEDLINE | ID: mdl-16630356

RESUMEN

BACKGROUND: Conventional methods for susceptibility testing require several months before results can be reported. However, rapid methods to determine drug susceptibility have been developed recently. Phage assay have been reported as a rapid useful tools for antimicrobial susceptibility testing. The aim of this study was to apply the Phage assay for rapid detection of resistance on Mycobacterium tuberculosis strains in Cuba. METHODS: Phage D29 assay was performed on 102 M. tuberculosis strains to detect rifampicin resistance. The results were compared with the proportion method (gold standard) to evaluate the sensitivity and specificity of Phage assay. RESULTS: Phage assay results were available in 2 days whereas Proportion Methods results were obtain in 42 days. A total of 44 strains were detected as rifampicin resistant by both methods. However, one strains deemed resistant by Proportion Methods was susceptible by Phage assay. The sensitivity and specificity of Phage assay were 97.8 % and 100% respectively. CONCLUSION: Phage assay provides rapid and reliable results for susceptibility testing; it's easy to perform, requires no specialized equipment and is applicable to drug susceptibility testing in low income countries where tuberculosis is a major public health problem.


Asunto(s)
Antibióticos Antituberculosos/farmacología , Farmacorresistencia Bacteriana , Micobacteriófagos/fisiología , Mycobacterium tuberculosis/efectos de los fármacos , Mycobacterium tuberculosis/virología , Rifampin/farmacología , Humanos , Pruebas de Sensibilidad Microbiana , Fenotipo , Sensibilidad y Especificidad , Factores de Tiempo
8.
J Microbiol Methods ; 63(2): 145-50, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15893391

RESUMEN

The performance of the nitrate reductase assay was evaluated in a multicenter laboratory study to detect resistance of Mycobacterium tuberculosis to the first-line anti-tuberculosis drugs rifampicin, isoniazid, ethambutol and streptomycin using a set of coded isolates. Compared with the gold standard proportion method on Löwenstein-Jensen medium, the assay was highly accurate in detecting resistance to rifampicin, isoniazid and ethambutol with an accuracy of 98%, 96.6% and 97.9%, respectively. For streptomycin, discrepant results were obtained with an overall accuracy of 85.3%. The assay proved easy to be implemented in countries with limited laboratory facilities.


Asunto(s)
Antituberculosos/farmacología , Farmacorresistencia Bacteriana , Mycobacterium tuberculosis/efectos de los fármacos , Mycobacterium tuberculosis/enzimología , Nitrato-Reductasa/metabolismo , Humanos , Pruebas de Sensibilidad Microbiana , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Tuberculosis/microbiología
9.
Biomedica ; 24 Supp 1: 80-4, 2004 Jun.
Artículo en Español | MEDLINE | ID: mdl-15495575

RESUMEN

Drug-resistance surveillance by means of culture and drug susceptibility test (DST) allows the estimation of the regional and global magnitude of multidrug-resistance (MDR). Two reports on anti-tuberculosis drug resistance by the WHO/IUATLD showed that drug-resistance TB varied widely across regions. This work determined the prevalence of drug resistance among new cases and among previously treated cases of tuberculosis in Cuba during the period 1995-1998. Drug resistance was determined using the proportion method in 1379 Mycobacterium tuberculosis strains to first line antituberculosis drugs (isoniazid, streptomycin, ethambutol and rifampicin). The resistance in new cases was 8.3% and 6.5%; MDR was 0.7% and 0% in the first and second study respectively. The contributed data through Cuba demonstrated that our country is relatively free of MDR strains, recognizing it to world level the good tuberculosis-control programs and the success of the application in our country of the directly-observed-treatment strategy from the year 1971.


Asunto(s)
Antituberculosos/farmacología , Farmacorresistencia Bacteriana , Mycobacterium tuberculosis/efectos de los fármacos , Antituberculosos/uso terapéutico , Cuba , Humanos , Vigilancia de la Población , Tuberculosis/tratamiento farmacológico , Tuberculosis/microbiología
10.
Biomedica ; 34 Suppl 1: 108-13, 2014 Apr.
Artículo en Español | MEDLINE | ID: mdl-24968042

RESUMEN

INTRODUCTION: Antituberculosis-drug resistance surveillance is very important to identify multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis isolates. OBJECTIVE: To determine the prevalence of resistance in M. tuberculosis strains isolated between 2010 and 2011, and to demonstrate the laboratory performance in the external quality control of drug susceptibility testing. MATERIALS AND METHODS: A prospective longitudinal study was carried out to determine antituberculosis-drug resistance in 657 M. tuberculosis isolates obtained throughout the country. The nitrate reductase assay was used to detect resistance to isoniazid and rifampin. The proportion method was performed to confirm resistance to these drugs and to further investigate in multidrug-resistant isolates their susceptibility to streptomycin, ethambutol, ofloxacin, kanamycin and capreomycin. Additionally, as part of external quality control, susceptibility was evaluated in two M. tuberculosis strain panels. RESULTS: In 95.69% of the isolates recovered from new tuberculosis cases, and in 72.64 % of isolates from previously treated patients we found susceptibility to isoniazid and rifampicin; multidrug resistance was 1,03 and 10.38%, respectively. We found two extensively resistant isolates. Except for ethambutol and capreomycin, the efficiency of all other drugs was 100% in the external quality control. CONCLUSION: The study confirmed the low prevalence of M. tuberculosis multidrug-resistant isolates in Cuba. This result was confirmed by the external quality control of drug susceptibility testing.


Asunto(s)
Antituberculosos/farmacología , Farmacorresistencia Bacteriana , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis/microbiología , Células Clonales/efectos de los fármacos , Cuba/epidemiología , Farmacorresistencia Bacteriana Múltiple , Humanos , Isoniazida/farmacología , Laboratorios/estadística & datos numéricos , Pruebas de Sensibilidad Microbiana/métodos , Mycobacterium tuberculosis/aislamiento & purificación , Vigilancia de la Población , Prevalencia , Estudios Prospectivos , Rifampin/farmacología , Tuberculosis/epidemiología , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Tuberculosis Resistente a Múltiples Medicamentos/microbiología
11.
Biomédica (Bogotá) ; 34(supl.1): 108-113, abr. 2014. tab
Artículo en Español | LILACS | ID: lil-712427

RESUMEN

Introducción. La vigilancia de la resistencia a medicamentos antituberculosos permite alertar sobre el hallazgo de aislamientos de Mycobacterium tuberculosis multirresistentes y extremadamente resistentes . Objetivo. Determinar los patrones de resistencia de los aislamientos de M. tuberculosis recuperados en Cuba entre los años 2010 y 2011 y demostrar el desempeño del Laboratorio Nacional de Referencia en la ejecución de las pruebas de sensibilidad. Materiales y métodos. Se realizó un estudio prospectivo longitudinal en el que se incluyeron 657 aislamientos de M. tuberculosis recibidos de todo el país. Se empleó el método de la nitrato reductasa para detectar resistencia a isoniacida y rifampicina, y el método de las proporciones para corroborar la resistencia a dichos medicamentos e investigar la sensibilidad a estreptomicina, etambutol, ofloxacina, kanamicina y capreomicina en aislamientos multirresistentes. Como parte del control de calidad externo de las pruebas de sensibilidad, se evaluaron dos paneles de cepas de M. tuberculosis . Resultados. En 95,69 % de los aislamientos recuperados de casos nuevos de tuberculosis y en 72,64 % de los recuperados de casos previamente tratados, se encontró sensibilidad a isoniacida y rifampicina, siendo la multirresistencia de 1,03 y 10,38 %, respectivamente. Se encontraron dos aislamientos extremadamente resistentes. Con la excepción del etambutol y la capreomicina, para todos los medicamentos la eficiencia fue de 100% en el control de calidad externo. Conclusiones. Se confirmó la baja prevalencia de aislamientos de M. tuberculosis multirresistentes en Cuba, resultado avalado por el excelente desempeño demostrado en el control de calidad externo de las pruebas de sensibilidad.


Introduction: Antituberculosis-drug resistance surveillance is very important to identify multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis isolates. Objective: To determine the prevalence of resistance in M. tuberculosis strains isolated between 2010 and 2011, and to demonstrate the laboratory performance in the external quality control of drug susceptibility testing. Materials and methods: A prospective longitudinal study was carried out to determine antituberculosis-drug resistance in 657 M. tuberculosis isolates obtained throughout the country. The nitrate reductase assay was used to detect resistance to isoniazid and rifampin. The proportion method was performed to confirm resistance to these drugs and to further investigate in multidrug-resistant isolates their susceptibility to streptomycin, ethambutol, ofloxacin, kanamycin and capreomycin. Additionally, as part of external quality control, susceptibility was evaluated in two M. tuberculosis strain panels. Results: In 95.69% of the isolates recovered from new tuberculosis cases, and in 72.64 % of isolates from previously treated patients we found susceptibility to isoniazid and rifampicin; multidrug resistance was 1,03 and 10.38%, respectively. We found two extensively resistant isolates. Except for ethambutol and capreomycin, the efficiency of all other drugs was 100% in the external quality control. Conclusion: The study confirmed the low prevalence of M. tuberculosis multidrug-resistant isolates in Cuba. This result was confirmed by the external quality control of drug susceptibility testing.


Asunto(s)
Humanos , Antituberculosos/farmacología , Farmacorresistencia Bacteriana , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis/microbiología , Células Clonales/efectos de los fármacos , Cuba/epidemiología , Farmacorresistencia Bacteriana Múltiple , Isoniazida/farmacología , Laboratorios/estadística & datos numéricos , Pruebas de Sensibilidad Microbiana/métodos , Mycobacterium tuberculosis/aislamiento & purificación , Vigilancia de la Población , Prevalencia , Estudios Prospectivos , Rifampin/farmacología , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Tuberculosis/epidemiología
12.
Rev. panam. salud pública ; 30(6): 615-618, Dec. 2011.
Artículo en Español | LILACS | ID: lil-612959

RESUMEN

Objetivo. Determinar la prevalencia de la resistencia a los fármacos antituberculosos en Cuba en el decenio 2000–2009. Métodos. Se realizó un estudio prospectivo longitudinal. El universo de trabajo estuvo constituido por un total de 2 285 aislamientos de Mycobacterium tuberculosis obtenidos de todo el país en el período comprendido entre el 1 de enero de 2000 y el 31 de diciembre de 2009. Se empleó el método de las proporciones en medio Löwenstein-Jensen con los fármacos de primera línea: isoniazida, estreptomicina, etambutol y rifampicina. Resultados. La resistencia entre los casos nuevos y los pacientes con antecedente de tratamiento previo fue de 8,5% y 37,0%, respectivamente; para estas mismas categorías de caso, la multirresistencia fue de 0,4% y 8,8%, respectivamente. Conclusiones. El presente estudio muestra baja prevalencia de cepas multirresistentes en Cuba. Estos resultados reflejan los avances logrados por el programa nacional de control, que trabaja en la actualidad hacia la eliminación de la tuberculosis como problema de salud pública en el país.


Objective. Determine the prevalence of resistance to antitubercular drugs in Cuba in the 2000–2009 decade. Methods. A prospective longitudinal study was conducted. The sample group consisted of 2 285 Mycobacterium tuberculosis isolates obtained from throughout the country in the period from 1 January 2000 to 31 December 2009. The proportion method was used in Löwenstein-Jensen media with the first-line drugs: isoniazid, streptomycin, ethambutol, and rifampicin. Results. In the new cases and patients with a history of previous treatment, resistance was 8.5% and 37.0%, respectively. In these case categories, multidrug resistance was 0.4% and 8.8%, respectively. Conclusions. This study shows low prevalence of multidrug-resistant strains in Cuba. The results reflect the progress made by the national control program, which is currently working on the elimination of tuberculosis as a public health problem in the country.


Asunto(s)
Humanos , Antituberculosos/farmacología , Farmacorresistencia Microbiana , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis/microbiología , Antituberculosos/uso terapéutico , Cuba/epidemiología , Farmacorresistencia Bacteriana Múltiple , Estudios de Seguimiento , Control de Infecciones/organización & administración , Mycobacterium tuberculosis/aislamiento & purificación , Vigilancia de la Población , Prevalencia , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Tuberculosis Resistente a Múltiples Medicamentos/prevención & control , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Tuberculosis/prevención & control
13.
J Antimicrob Chemother ; 55(4): 500-5, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15731200

RESUMEN

OBJECTIVES: To evaluate the performance of three rapid low-cost methods for the detection of resistance to first-line drugs in Mycobacterium tuberculosis. METHODS: One hundred M. tuberculosis clinical isolates were tested by the nitrate reductase assay (NRA), the MTT test and the resazurin microtitre assay (REMA), and the results compared with those obtained with the gold standard proportion method (PM) on Lowenstein Jensen medium. RESULTS: The results using the three methods showed a good sensitivity and specificity between 94% and 100% for the detection of rifampicin and isoniazid resistance. Specificity for ethambutol and streptomycin using MTT and resazurin was low (58-89%). In contrast, NRA showed a good agreement for all first-line drugs tested. CONCLUSIONS: This study shows a high level of agreement of these three low-cost methods compared with the PM for rapid detection of rifampicin and isoniazid resistance. However, more standardization is needed for ethambutol and streptomycin using the MTT test and resazurin microtitre assay. The nitrate reductase assay might represent an inexpensive procedure for rapid detection of resistance to first-line drugs in low-resource countries.


Asunto(s)
Antituberculosos/farmacología , Pruebas de Sensibilidad Microbiana/métodos , Mycobacterium tuberculosis/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple , Etambutol/farmacología , Formazáns , Isoniazida/farmacología , Mycobacterium tuberculosis/metabolismo , Nitrato-Reductasa , Nitrato Reductasas/metabolismo , Oxazinas , Rifampin/farmacología , Sensibilidad y Especificidad , Estreptomicina/farmacología , Sales de Tetrazolio , Xantenos
14.
J Antimicrob Chemother ; 54(1): 130-3, 2004 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15190018

RESUMEN

OBJECTIVE: To study the performance of three rapid low cost methods for the detection of rifampicin resistance. METHODS: A panel of 20 coded Mycobacterium tuberculosis strains was tested blindly by the low cost methods: nitrate reductase, MTT and resazurin assays, and compared with the results obtained with the gold standard methods: the proportion method on Löwenstein-Jensen medium and the BACTEC TB 460 system. We have also tested two commercial tests: MGIT and INNO LiPA Rif.TB kit. RESULTS: Complete agreement was observed among all methods. CONCLUSION: These three simple methods might become inexpensive alternative procedures for rapid detection of rifampicin resistance in low-resource countries.


Asunto(s)
Antibióticos Antituberculosos/farmacología , Pruebas de Sensibilidad Microbiana/métodos , Mycobacterium tuberculosis/efectos de los fármacos , Rifampin/farmacología , Xantenos , Colorimetría , Medios de Cultivo , ARN Polimerasas Dirigidas por ADN/genética , Farmacorresistencia Bacteriana , Humanos , Indicadores y Reactivos , Pruebas de Sensibilidad Microbiana/economía , Nitrato-Reductasa , Nitrato Reductasas/metabolismo , Oxazinas , Oxidación-Reducción , Perú , Juego de Reactivos para Diagnóstico , Sales de Tetrazolio , Tiazoles , Tuberculosis/microbiología
15.
Rev. argent. microbiol ; 45(1): 21-6, mar. 2013.
Artículo en Español | LILACS, BINACIS | ID: biblio-1171772

RESUMEN

The relation of ethambutol resistance to embB mutations remains unclear, and there are no reports on ethambutol resistance from the caribbean. We examined the sequence of embB in 57 distinct Multi-Drug Resistant (MDR) and non-MDR strains of Mycobacterium tuberculosis, mostly from Cuba and the Dominican Republic. embB306 codon mutations were found exclusively in MDR-TB, but in both ethambutol sensitive and resistant strains. Valine substitutions predominated in ethambutol resistant strains, while isoleucine replacements were more common in sensitive strains. Three ethambutol resistant MDR strains without embB306 substitutions had replacements in embB406 or embB497, but these were also found in ethambutol sensitive MDR strains. The results confirm previous findings that amino acid substitutions in EmbB306, EmbB406 and EmbB497 are found only in MDR-TB strains but in both phenotypically resistant and sensitive strains. One ethambutol resistant non-MDR strain did not have any embB mutation suggesting that other undefined mutations can also confer ethambutol resistance.


Asunto(s)
Antituberculosos/farmacología , Etambutol/farmacología , Mycobacterium tuberculosis/genética , Pentosiltransferasa/genética , Farmacorresistencia Microbiana/genética , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Análisis Mutacional de ADN , Cuba/epidemiología , Codón/genética , ADN Bacteriano/genética , Farmacorresistencia Bacteriana Múltiple/genética , Humanos , Mutación , Mycobacterium tuberculosis/efectos de los fármacos , Pentosiltransferasa/fisiología , Relación Dosis-Respuesta a Droga , Reproducibilidad de los Resultados , República Dominicana/epidemiología , Sensibilidad y Especificidad , Sustitución de Aminoácidos , Pruebas de Sensibilidad Microbiana , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología
16.
Biomédica (Bogotá) ; 24(supl.1): 80-84, jun. 2004. tab
Artículo en Español | LILACS | ID: lil-635452

RESUMEN

L a vigilancia de la resistencia a fármacos a través del cultivo y de las pruebas de susceptibilidad in vitro permite conocer la magnitud regional y mundial de la resistencia en tuberculosis. En el presente trabajo se determinó la prevalencia de la resistencia a fármacos antituberculosos en Cuba, durante el periodo 1995-1998 en casos nuevos y en aquéllos que han recibido tratamiento previo. Los resultados incluidos en este estudio forman parte de los dos proyectos mundiales organizados por la OMS/UICTER. La resistencia a los medicamentos se evaluó usando el método de las proporciones en 1.379 cepas de Mycobacterium tuberculosis a los fármacos de primera línea (isoniacida, rifampicina, estreptomicina y etambutol). La resistencia en casos nuevos fue del 8,3% y 6,5% y la resistencia múltiple a fármacos ( multidrug-resistance, MDR) fue del 0,7% y 0% en el primer y segundo estudio, respectivamente. Estos resultados permitieron demostrar la escasa circulación de cepas MDR en Cuba; se reconoció a nivel mundial el buen funcionamiento del Programa Nacional de Control y el éxito de la aplicación en nuestro país de la estrategia del tratamiento estrictamente supervisado desde 1971.


Surveillance of resistance of Mycobacterium tuberculosis to anti-TB drugs in Cuba, 1995-1998 Drug-resistance surveillance by means of culture and drug susceptibility test (DST) allows the estimation of the regional and global magnitude of multidrug-resistance (MDR). Two reports on anti-tuberculosis drug resistance by the WHO/IUATLD showed that drug-resistance TB varied widely across regions. Thecurrent study determined the prevalence of drug resistance among new cases and among previously treated cases of tuberculosis in Cuba during the period 1995-1998. Using the proportion method, drug resistance was determined in 1,379 Mycobacterium tuberculosis strains to four front-line anti- tuberculosis drugs (isoniazid, streptomycin, ethambutol and rifampicin). In two separate studies, the overall resistance in new cases was 8.3% and 6.5%, and the MDR was 0.7% and 0%, respectively. The Cuba data demonstrated that Colombia, in comparison, is relatively free of MDR strains, indicating effective tuberculosis control programs in Colombia and the success of the direct observation-treatment strategy that has been in continuous use since 1971.


Asunto(s)
Humanos , Antituberculosos/farmacología , Farmacorresistencia Bacteriana , Mycobacterium tuberculosis/efectos de los fármacos , Antituberculosos/uso terapéutico , Cuba , Vigilancia de la Población , Tuberculosis/tratamiento farmacológico , Tuberculosis/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA